Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Balance Sheet: Assets
- Analysis of Long-term (Investment) Activity Ratios
- Analysis of Geographic Areas
- Present Value of Free Cash Flow to Equity (FCFE)
- Operating Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Price to Earnings (P/E) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
- Debt to Equity Ratio
- The debt to equity ratio exhibits an initial increase from 0.06 at the end of March 2020 to a peak of 0.27 in September 2020. Following this peak, the ratio shows a consistent downward trend, declining steadily to reach 0.09 by June 2025. This trend suggests a gradual reduction in leverage relative to shareholders' equity over the observed periods.
- Debt to Capital Ratio
- Similar to the debt to equity ratio, the debt to capital ratio rises early in the timeline, peaking at 0.21 in September 2020 before steadily declining thereafter. The ratio decreases to 0.08 by June 2025, indicating an improvement in the company's capital structure with lesser reliance on debt over time.
- Debt to Assets Ratio
- The debt to assets ratio follows a comparable trajectory, increasing initially to 0.17 in September 2020, then progressively decreasing to 0.07 by June 2025. This decline points to a reduction in the proportion of assets financed through debt, enhancing the financial stability of the company.
- Financial Leverage Ratio
- The financial leverage ratio rises from 1.3 in March 2020 to a high of 1.59 in June and September 2020, followed by a gradual decline and stabilization around 1.27 to 1.29 from late 2021 onward. This pattern indicates that the company initially increased its use of debt relative to equity but later maintained a moderately stable leverage position.
- Interest Coverage Ratio
- The interest coverage ratio data begins from December 2020 and displays a significant upward spike early on, reaching a maximum of 163.75 in March 2022. This high coverage suggests strong earnings available to cover interest expenses during that period. Following the peak, the ratio declines steadily to around 57.85 by June 2024. However, it increases again afterwards, reaching 134.19 by June 2025, reflecting improved ability to meet interest obligations toward the end of the period.
Debt Ratios
Coverage Ratios
Debt to Equity
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
Debt | |||||||||||||||||||||||||||||
Finance lease liabilities, current portion | |||||||||||||||||||||||||||||
Long-term debt | |||||||||||||||||||||||||||||
Finance lease liabilities, excluding current portion | |||||||||||||||||||||||||||||
Total debt | |||||||||||||||||||||||||||||
Stockholders’ equity | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Debt to equity1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Debt to Equity, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The data reveals key trends in the company's total debt, stockholders’ equity, and debt-to-equity ratio over a period spanning from March 31, 2020, to June 30, 2025. The analysis highlights notable fluctuations and overall direction in these financial metrics.
- Total Debt
- Total debt exhibited a significant increase from approximately $715 million at the end of Q1 2020 to around $2.7 billion by Q1 2021. Following this sharp rise, total debt stabilized and remained relatively constant, hovering around the $2.7 billion mark through to mid-2025 with minor incremental increases. This pattern suggests a major debt issuance or reclassification event between Q1 2020 and Q1 2021, followed by debt management aimed at maintaining consistent leverage levels.
- Stockholders’ Equity
- Stockholders’ equity showed an initial decline from $12.1 billion in Q1 2020 to about $9.1 billion by Q2 2020. Subsequently, equity increased steadily and robustly, reaching approximately $15.1 billion by mid-2021 and continuing an upward trend to nearly $29.9 billion by mid-2025. This growth reflects strong retained earnings or capital inflows, enhancing the company's net worth significantly over the nearly five-year period.
- Debt-to-Equity Ratio
- The debt-to-equity ratio rose sharply from 0.06 in Q1 2020 to 0.27 by Q3 2020, coinciding with the substantial increase in total debt and simultaneous drop in equity. After peaking, the ratio declined steadily to 0.09 by mid-2025. This downward trend implies that equity growth outpaced the growth of debt following the initial peak, indicating strengthening financial stability and a more conservative leverage posture over time.
In summary, the company experienced an initial phase of increased leverage driven by higher debt and reduced equity early in the observed period. However, this was followed by sustained equity growth and stabilization of debt levels, resulting in a gradual reduction of the debt-to-equity ratio. The financial structure evolved toward lower relative debt exposure, which may imply improved creditworthiness and balance sheet strength in the later periods.
Debt to Capital
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
Debt | |||||||||||||||||||||||||||||
Finance lease liabilities, current portion | |||||||||||||||||||||||||||||
Long-term debt | |||||||||||||||||||||||||||||
Finance lease liabilities, excluding current portion | |||||||||||||||||||||||||||||
Total debt | |||||||||||||||||||||||||||||
Stockholders’ equity | |||||||||||||||||||||||||||||
Total capital | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Debt to capital1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Debt to Capital, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
Over the analyzed periods, total debt exhibited a sharp increase from March 31, 2020, to June 30, 2020, rising from approximately 715 million to over 2.2 billion US dollars. Following this significant jump, total debt continued to increase but at a much slower and steady pace, gradually rising to around 2.7 billion by the end of 2025.
Total capital demonstrated a fluctuating yet generally upward trend over the same timeframe. Initially, total capital decreased from about 12.8 billion in March 2020 to roughly 11.3 billion by June 2020. Subsequently, total capital exhibited sustained growth, reaching approximately 32.6 billion by mid-2025. This denotes an overall positive expansion in capital, with notable growth phases especially from 2021 onwards.
The debt to capital ratio experienced a significant increase in the early part of the timeline, escalating from 0.06 in March 2020 to around 0.2 by mid-2020. Thereafter, this ratio steadily declined over the succeeding quarters, moving down to around 0.08 by June 2025. The diminishing trend in the debt to capital ratio suggests an improvement in the company's leverage position relative to its capital base, indicating a possible reduction in financial risk over time despite the increase in absolute debt value.
Overall, the data reflects an initial period of increased borrowing relative to capital, followed by a phase characterized by growth in total capital and a concurrent reduction in leverage ratios, signaling a strengthening capital structure over the long term.
Debt to Assets
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
Debt | |||||||||||||||||||||||||||||
Finance lease liabilities, current portion | |||||||||||||||||||||||||||||
Long-term debt | |||||||||||||||||||||||||||||
Finance lease liabilities, excluding current portion | |||||||||||||||||||||||||||||
Total debt | |||||||||||||||||||||||||||||
Total assets | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Debt to assets1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Debt to Assets, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The financial data reveals the following key trends and observations over the observed periods:
- Total Debt
- Total debt increased sharply from March 2020 to June 2020, rising from approximately $715 million to about $2.2 billion. Following this significant rise, the debt level continued to grow but at a much slower and steadier pace, gradually inching from around $2.7 billion in late 2020 to just over $2.7 billion by mid-2025. The incremental increases after mid-2020 are minimal, suggesting a stabilization of debt levels near the $2.7 billion mark.
- Total Assets
- Total assets fluctuated notably throughout the period. Initially, assets decreased from about $15.8 billion in March 2020 to $14.4 billion by mid-2020 but then showed a steady rising trajectory afterward. Assets rose consistently from late 2020 onward, reaching approximately $38.2 billion by mid-2025. This represents a more than doubling of total assets from the low point observed in mid-2020, indicating strong asset growth.
- Debt to Assets Ratio
- The debt to assets ratio reflects the changes in both debt and assets, starting at a low level of around 0.05 in early 2020. It increased significantly to approximately 0.17 by September 2020 coinciding with the peak in debt levels and dip in asset value. Following this peak, the ratio shows a generally declining trend, decreasing steadily to about 0.07 by mid-2025. This decline suggests that asset growth outpaced the growth in debt, improving the company’s leverage position over the later periods.
Overall, the data suggests that despite a high increase in total debt in early 2020, the company has been effective in expanding its asset base substantially thereafter, resulting in a lower debt-to-asset ratio over time. The stabilization of debt coupled with sustained asset growth indicates improving financial leverage and potentially greater financial stability over the medium term.
Financial Leverage
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
Total assets | |||||||||||||||||||||||||||||
Stockholders’ equity | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Financial leverage1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Financial Leverage, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several notable trends in total assets, stockholders’ equity, and financial leverage over the examined periods.
- Total Assets
- Total assets have exhibited a generally increasing trend over the quarters, moving from approximately $15.8 billion in the first quarter of 2020 to around $38.2 billion by mid-2025. There was an initial dip observed between March 2020 and June 2020, followed by a consistent upward trajectory thereafter. This growth reflects an expansion in the company’s asset base, suggesting increased investments or acquisitions of assets over time.
- Stockholders’ Equity
- Stockholders’ equity followed a somewhat similar but less volatile path. Starting at roughly $12.1 billion in early 2020, equity experienced a notable decline during the same period when total assets dipped, reaching about $9.1 billion by June 2020. Subsequently, equity levels consistently rose, peaking near $29.9 billion by the end of 2024, before stabilizing slightly thereafter in 2025. The growth in equity indicates retained earnings and possible new equity issuances contributing to the company’s net worth improvements.
- Financial Leverage
- The financial leverage ratio demonstrated a marked transition over time. Initially, in early 2020, the ratio was lower at 1.3 but increased to approximately 1.59 during June and September 2020, indicating a higher proportion of debt relative to equity during that period. From late 2020 onwards, the ratio steadily declined, reaching a stable range near 1.28 from 2022 through mid-2025. The gradual decrease and stabilization of leverage suggest the company has been reducing its debt relative to equity or increasing equity faster than debt, leading to an improved capital structure with lower financial risk over the long term.
In summary, the data depicts a company expanding its asset base and strengthening its equity position over the years, while concurrently improving its leverage ratio. The initial disruptions in early 2020 may reflect external economic challenges or internal restructuring, but the subsequent recovery and growth trends suggest a strategic focus on financial stability and growth. The stable and relatively low financial leverage in recent periods points to prudent financial management and balanced use of debt financing.
Interest Coverage
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
Net income | |||||||||||||||||||||||||||||
Add: Income tax expense | |||||||||||||||||||||||||||||
Add: Interest expense | |||||||||||||||||||||||||||||
Earnings before interest and tax (EBIT) | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Interest coverage1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Interest Coverage, Competitors2 | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Interest coverage
= (EBITQ2 2025
+ EBITQ1 2025
+ EBITQ4 2024
+ EBITQ3 2024)
÷ (Interest expenseQ2 2025
+ Interest expenseQ1 2025
+ Interest expenseQ4 2024
+ Interest expenseQ3 2024)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Earnings before interest and tax (EBIT)
- The EBIT values exhibit moderate volatility over the periods observed. From March 2020 to December 2020, there is a steady increase from approximately 675 million USD to nearly 1.24 billion USD. The figure peaks significantly in June 2021 at around 3.77 billion USD, marking the highest value in the series, followed by a sharp decline to approximately 1.83 billion USD in September 2021. Afterward, EBIT stabilizes within a range between 870 million USD and 1.57 billion USD through to December 2024, with several fluctuations. Notably, there is a downward trend toward early 2025 with EBIT falling under 1 billion USD in March and June 2025 before rising again to about 1.52 billion USD.
- Interest expense
- The interest expense remains relatively stable throughout the entire period, fluctuating between 3.6 million USD and 26.3 million USD. The highest expenses occur early in the dataset, particularly in September 2020 with around 26.3 million USD, followed by a gradual decrease toward mid-2025 when interest expenses reach their lowest values under 9 million USD. This suggests a declining trend in borrowing costs or reductions in debt levels over time.
- Interest coverage ratio
- This ratio, which indicates the company's ability to cover interest costs through EBIT, shows considerable improvement from late 2020 onward. Starting with a ratio around 68 in March 2020, it rapidly increases and peaks above 163 in December 2021. Thereafter, the ratio experiences some decline but remains well above 50 across all subsequent quarters, reaching values over 130 in mid-2025. This improvement indicates enhanced capacity to service interest expenses, largely driven by increased EBIT and controlled interest costs.
- Overall observations
- The financial data reveals strong operational profitability peaks, particularly in mid-2021, though EBIT exhibits some fluctuations over time. Meanwhile, interest expenses decline steadily, contributing to an improved interest coverage ratio throughout the period. The enhanced interest coverage ratio reflects increased financial stability and reduced risk concerning debt servicing. Despite some volatility in EBIT, the company maintains a robust ability to meet interest obligations consistently, which is a positive indicator of financial health.